ClinicalTrials.gg
Not yet recruitingNCT07568821Updated May 11, 2026

Effectiveness of VR Rehabilitation for People With Asymmetrical Gait Patterns

An interventional study of Virtual Reality (VR) and Standard Rehabilitation and Standard Rehabilitation in Disability Evaluation, Recovery of Function and Rehabilitation, sponsored by University of Rzeszow. Not yet recruiting. Open to participants aged 20 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-05-11.

Sponsored by University of Rzeszow · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
20 Years to 65 Years
Sex
All
01

Study summary

A randomized comparative study will be conducted to evaluate the rehabilitation process using a VR-based application versus conventional therapy in 40 patients (sample size determined using a sample size calculator). After meeting the eligibility criteria, participants will be randomly assigned to two groups: the experimental group (20 patients with gait pattern asymmetry), performing a gait training program using a VR rehabilitation application, and the control group (20 patients with gait pattern asymmetry), performing only a conventional gait training program.

Participants in both groups will take part in a 2-week rehabilitation program (Monday to Friday), with daily training sessions lasting up to 2 hours. Patient assessment will be conducted twice: an initial evaluation before the start of the intervention (Assessment I) and a follow-up evaluation after completion of the 2-week program (Assessment II), at the same time of day, under the same conditions, and using the same measurement tools.

Read the detailed description

Individuals with a diagnosed and clinically confirmed asymmetry of gait pattern will be eligible for inclusion in the study.

Exclusion criteria: Active rheumatic diseases, cancer, advanced diabetes, cardiovascular diseases, and other conditions affecting the safety and effectiveness of rehabilitation, Contraindications to VR therapy (epilepsy, motion sickness, dizziness, nausea), Lower limb injuries or surgeries within the last 6 months, Severe mental disorders preventing understanding of instructions.

Training for both groups will include balance and coordination exercises, proprioceptive stimulation, and exercises aimed at improving step length symmetry and lower limb loading. Additionally, the experimental group will receive 15 to 30 minutes (adjusted to the patient's abilities) of training using a VR application in a virtual environment, providing real-time feedback on body position, step length, and balance. The effects of gait training will be evaluated using the following measures: gait speed, walking endurance, independent mobility and risk of falls, balance, gait symmetry, spinal mobility, and functional performance.

02

Conditions studied

  • Disability Evaluation
  • Recovery of Function
  • Rehabilitation
03

In context

Lead sponsor

University of Rzeszow is the lead sponsor of 37 studies on the registry; 12 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed and clinically confirmed gait pattern asymmetry in the course of neurological diseases
  • to participate in the study and willingness to comply with rehabilitation recommendations

Exclusion criteria

Exclusion Criteria:

  • Active rheumatic diseases, cancer, advanced diabetes, cardiovascular diseases, and other conditions that may affect the safety and effectiveness of rehabilitation
  • to VR therapy (epilepsy, motion sickness, dizziness, nausea)
  • Lower limb injuries or surgeries within the last 6 months
  • Severe mental disorders preventing understanding of instructions
  • Lack of to participate in the study
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    VR Therapy and Standard Rehabilitation

    Other: Virtual Reality (VR) and Standard Rehabilitation

  • Other
    Control: Standard Rehabilitation

    Other: Standard Rehabilitation

Interventions

  • OtherVirtual Reality (VR) and Standard Rehabilitation

    The experimental group will participate in a gait training program using a VR rehabilitation application. Participants will take part in a 2-week rehabilitation program (Monday to Friday), with daily training sessions lasting up to 2 hours. Training will include balance and coordination exercises, proprioceptive stimulation, and exercises aimed at improving step length symmetry and lower limb loading. Additionally, the experimental group will receive 15 to 30 minutes (adjusted to the patient's abilities) of training using a VR application in a virtual environment, providing real-time feedback on body position, step length, and balance.

  • OtherStandard Rehabilitation

    The control group will participate only in a conventional gait training program. Participants will take part in a 2-week rehabilitation program (Monday to Friday), with daily training sessions lasting up to 2 hours. Training will include balance and coordination exercises, proprioceptive stimulation, and exercises aimed at improving step length symmetry and lower limb loading.

06

What researchers measure

Primary outcomes

  1. Gait speed - 10-meter walk test

    Time frame: Baseline (Day 1)

  2. Gait speed - 10-meter walk test

    Time frame: Immediately after therapy completion (Day 10)

  3. Walking Endurance - 6-Minute Walk Test

    Time frame: Baseline (Day 1)

  4. Walking Endurance - 6-Minute Walk Test

    Time frame: Immediately after therapy completion (Day 10)

  5. Independent Mobility and Fall Risk - Timed "Get Up & Go" Test

    Time frame: Baseline (Day 1)

  6. Independent Mobility and Fall Risk - Timed "Get Up & Go" Test

    Time frame: Immediately after therapy completion (Day 10)

  7. Lower Limb Loading Symmetry - Two-Scale Test

    Time frame: Baseline (Day 1)

  8. Lower Limb Loading Symmetry - Two-Scale Test

    Time frame: Immediately after therapy completion (Day 10)

Secondary outcomes

  1. Gait and Balance - Dynamic Gait Index

    Time frame: Baseline (Day 1)

  2. Gait and Balance - Dynamic Gait Index

    Time frame: Immediately after therapy completion (Day 10)

  3. Gait Asymmetry - Wisconsin Gait Scale

    The Wisconsin Gait Scale is an observational tool used to assess gait quality. Scores range from 13.35 to 42, with higher scores indicating worse gait performance.

    Time frame: Baseline (Day 1)

  4. Gait Asymmetry - Wisconsin Gait Scale

    The Wisconsin Gait Scale is an observational tool used to assess gait quality. Scores range from 13.35 to 42, with higher scores indicating worse gait performance.

    Time frame: Immediately after therapy completion (Day 10)

07

Study locations

No study locations are listed for this record.

08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07568821
Lead sponsor
University of Rzeszow
Responsible party
Agnieszka Guzik, PhD (Principal investigator, University of Rzeszow) — Principal investigator
First posted
May 6, 2026
Start date
Mar 1, 2027 (estimated)
Primary completion
Jun 1, 2027 (estimated)
Completion
Aug 1, 2027 (estimated)
Last update
May 11, 2026

Study contacts

Agnieszka Guzik
Contact
aguzik@ur.edu.pl
+48 17 851 8965
Agnieszka Guzik
principal investigator · Rzeszów, Al. Rejtana 16C, Poland 35-310

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion